In the parotid glands of patients with a prior confirmed COVID-19 diagnosis, only METTL3 expression levels were significantly decreased (8.6 ± 5.7 vs. 22.7 ± 6.5 ng/mL; p = 0.03), whereas FTO levels showed no significant difference (4.4 ± 2.9 vs. 4.7 ± 3.7 ng/mL) (Figure 1). This evidence concerns the gene METTL3 and COVID-19.